Citius Pharmaceuticals (CTXR) Stock Forecast & Price Target

Citius Pharmaceuticals is a biopharmaceutical company with a positive growth outlook due to its flagship product candidate, LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein that offers a differentiated mechanism of action in treating CTCL. The commercial distribution of LYMPHIR commenced in December 2025 and generated $5.6M in sales in 1H FY2026. It also has two late-stage clinical candidates and a successful regulatory pathway for its antibiotic lock solution, Mino-Lok, which could add another leg of growth. With a projected peak market penetration of 10%, LYMPHIR could generate sales of $156M in FY2031 from $21M in FY2026. The company recorded a net loss of $0.95 per diluted share in 2Q FY2026, which is expected to improve sequentially, with projected profitability starting in FY2028. Efficacy signals for LYMPHIR were notable with an overall response rate of 86% and a 12-month overall survival estimated at 86%. Investors should stay tuned for a webinar with the CEO on March 11th to learn more about the company's recent progress and commercialization strategy for LYMPHIR.

Citius Pharmaceuticals is facing a negative outlook due to the small size of their flagship product candidate LYMPHIR's Phase 1 trial enrollment, and the relatively high number of patients who experienced cytokine release syndrome (43%) and immune effector cell-associated neurotoxicity syndrome (2%). The company has only one operating and reportable segment and is heavily focused on developing and commercializing targeted oncology therapies, posing a potential risk if other product candidates do not receive approval or are not successful in the market.